As a condition of publication of phase III clinical trials, medical journals should insist on the release of all raw data and a written independent clinical audit
Editorials and commentaries in some high-profile journals herald an upcoming revolution in personalised oncology.1 However, any new treatment can only be considered an advance if it:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.